Pyxis Oncology, Inc.
PYXS
$1.05
$0.0050.48%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -4.80% | 39.17% | 40.15% | 46.76% | 38.87% |
| Total Depreciation and Amortization | 54.75% | 118.47% | 163.47% | 285.02% | 171.79% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 121.60% | -66.80% | -58.68% | -56.99% | -51.02% |
| Change in Net Operating Assets | -0.55% | -74.38% | -232.33% | -178.67% | -359.14% |
| Cash from Operations | 18.44% | 26.37% | 25.41% | 27.03% | 20.85% |
| Capital Expenditure | 96.48% | 97.24% | 97.67% | 76.01% | -5.11% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -99.98% | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 108.01% | 93.01% | 92.99% | 70.46% | -- |
| Cash from Investing | 107.78% | 92.92% | 98.67% | 77.33% | -1,538.52% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 834.52% | 838.13% | 722.20% | 805,342.86% | 3,383.06% |
| Repurchase of Common Stock | 46.07% | 25.70% | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 900.61% | 895.15% | 836.63% | 906,185.71% | 3,139.89% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 105.78% | 98.55% | 99.58% | 87.08% | -77.53% |